MDAI

5,6-Methylenedioxy-2-aminoindane (MDAI) is a synthetic entactogen from the aminoindane family. It is structurally related to MDMA, but its amphetamine side chain is incorporated into a ring. MDAI was developed as a research chemical in the 1990s and appeared on the recreational drug market in the late 2000s. It is known for its serotonergic activity and has been associated with serotonin toxicity and several deaths, although recent human research has begun to clarify its acute effects.

Chemistry and history

MDAI contains a methylenedioxy group fused to an indane ring and an amino group at the 2-position. The cyclic structure distinguishes it from MDMA and MDA, while retaining the methylenedioxy substitution associated with entactogenic amphetamines.

Recreational use was reported in Europe from around 2007 and increased in the UK after 2009. It was sold online and in head shops as a legal alternative to MDMA, sometimes under names such as “Mindy” or “Sparkle”.

Pharmacology

MDAI interacts with the dopamine, norepinephrine and serotonin transporters, but shows a preference for serotonin and norepinephrine over dopamine. A study of aminoindanes found that MDAI was moderately selective for SERT and NET, with substantially weaker activity at DAT. This profile is consistent with its description as a relatively serotonin-oriented entactogen (2-Aminoindan and its ring-substituted derivatives, 2019).

Animal studies have reported MDMA-like behavioural effects and serotonin release. The evidence for neurotoxicity is mixed: some early work suggested a lower neurotoxic profile than MDMA, while later experiments identified serotonergic toxicity under particular experimental conditions.

Subjective effects

The PsychonautWiki profile of MDAI describes emotional warmth and sociability as more prominent than strong stimulation in the entactogenic experience. Human evidence remains limited, but a 2024 self-administration study provides direct observations from six healthy volunteers.

In that study, MDAI produced subjective effects qualitatively comparable to those reported for a higher MDMA reference condition. Participants showed increased blood pressure, cortisol and prolactin, but no measurable increase in heart rate or body temperature. The study was non-blinded, had no placebo group and included only six people, so its findings are preliminary rather than a clinical safety assessment (Angerer and colleagues, 2024).

Emotional and cognitive effects

Reports describe empathy, affection, emotional openness and increased feelings of closeness. Music appreciation and sociability are also mentioned. Compared with MDMA, MDAI is often described as less stimulating, although the limited human study found subjective effects that were broadly similar in quality.

Physical effects

Reported physical effects include increased blood pressure, sweating, jaw tension and reduced appetite. Some accounts mention nausea, headaches and difficulty sleeping. The 2024 volunteer study did not observe an increase in heart rate or body temperature, but its small size does not rule out adverse reactions in other circumstances.

Toxicity and clinical reports

A 2013 review described the first three UK deaths associated with MDAI use in 2011 and 2012. Serotonin syndrome was considered a possible factor in these fatalities, although the evidence base was small and some cases involved other substances (Corkery and colleagues, 2013).

Animal research has also raised concerns about serotonergic toxicity and behavioural disruption. These findings do not establish the risk of repeated exposure in humans, but they show why MDAI should not be assumed to be a harmless or non-neurotoxic alternative to MDMA.

Related compounds

MDAI is related to 5-APB, MDMA and other methylenedioxy-substituted entactogens. Its aminoindane structure distinguishes it from the open-chain amphetamine compounds.